BRIEF-Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial

Reuters
Jul 31
BRIEF-Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial

July 31 (Reuters) - Pasithea Therapeutics Corp KTTA.O:

  • PASITHEA THERAPEUTICS COMPLETES ENROLLMENT AND INITIAL DOSING OF FIRST COHORT FROM ITS PHASE 1/1B CLINICAL TRIAL OF PAS-004 IN ADULT NF1 PATIENTS

Source text: ID:nGNXQqjP6

Further company coverage: KTTA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10